✨ Brinzolamide Intermediate (CAS 154127-42-1) ✨
🔍 Google Search Keywords: Brinzolamide Intermediate, CAS 154127-42-1, Ophthalmic API Intermediate, Carbonic Anhydrase Inhibitor Synthesis, Pharmaceutical Intermediates
📌 Product Overview
Brinzolamide Intermediate (CAS 154127-42-1) is a high-purity chemical compound essential for synthesizing Brinzolamide, a top-tier carbonic anhydrase inhibitor used to treat glaucoma and ocular hypertension. This intermediate ensures precise and efficient production of the active pharmaceutical ingredient (API) for ophthalmic therapeutics.
Main Function: Critical building block in Brinzolamide API synthesis.
Applications: Pharmaceutical manufacturing, ophthalmic drug development, API production.
✅ Key Benefits
🧪 Ultra-High Purity | ⚡ Optimized Synthesis | 🌡️ Enhanced Stability |
---|
Purity ≥99% (HPLC) | Reduces synthesis steps by 25% | Stable under controlled storage |
📦 Batch Consistency | 💊 Regulatory Compliance |
---|
Meets pharmacopeial specs | Supports cGMP and ICH guidelines |
🔬 Application Areas
Glaucoma Drug Production: Core intermediate for Brinzolamide API.
Ophthalmic Formulations: Enables scalable manufacturing of eye drop solutions.
Contract Manufacturing: Ideal for large-scale API production.
Generic Drug Development: Facilitates cost-effective alternatives to branded therapies.
📜 Quality Certifications
Testing Standards: HPLC, GC, NMR, Mass Spectrometry.
Compliance: USP, EP, ICH Q7 standards.
Packaging: Sealed in moisture-proof containers, stored at 2-8°C.
📈 Market Trends
The global Brinzolamide market is projected to grow at 5.2% CAGR (2024-2030), driven by increasing glaucoma prevalence and aging populations. Demand for high-quality intermediates surges as generic ophthalmic drugs gain FDA and EMA approvals.


